Regenxbio provides update on interim results of retinal and Duchenne programs

Regenxbio announced new interim data from the Phase II AAVIATE and ALTITUDE trials of ABBV-RGX-314 suprachoroidal delivery in wet AMD and diabetic retinopathy – DR -. The company also provided a comprehensive Duchenne program overview including initial safety data for RGX-202 and a new exon 53 program. Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation. Initial safety results from Cohort 1 of the AFFINITY DUCHENNE study support well-tolerated profile to date; initial efficacy data to be presented at World Muscle Society meeting in October. A new program in Duchenne with preclinical data using innovative science to produce near full-length wild-type dystrophin; expects to file IND to the FDA in the first half of 2025.